XML 28 R17.htm IDEA: XBRL DOCUMENT
v3.25.3

Identifiable Intangible Assets, Net and Goodwill | 9 Months Ended
--- | ---
Sep. 28, 2025
Goodwill and Intangible Assets Disclosure [Abstract] |
Identifiable Intangible Assets, Net and Goodwill | Identifiable Intangible Assets, Net and Goodwill A. Identifiable Intangible Assets
The following summarizes the components of Identifiable intangible assets:
|  | September 28, 2025 |  | December 31, 2024
(MILLIONS) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Identifiable Intangible Assets, Net |  | Gross Carrying Amount |  | Accumulated Amortization |  | Identifiable Intangible Assets, Net
Finite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |
Developed technology rights(a) |  | $ | 101,220 |  |  | $ | (69,057) |  |  | $ | 32,163 |  |  | $ | 99,397 |  |  | $ | (65,044) |  |  | $ | 34,353 |
Brands |  | 1,274 |  |  | (1,023) |  |  | 251 |  |  | 1,277 |  |  | (992) |  |  | 285 |
Licensing agreements and other |  | 2,355 |  |  | (1,256) |  |  | 1,099 |  |  | 2,724 |  |  | (1,513) |  |  | 1,210 |
|  | 104,849 |  |  | (71,337) |  |  | 33,513 |  |  | 103,397 |  |  | (67,549) |  |  | 35,848 |
Indefinite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |
IPR&D(a), (b) |  | 17,350 |  |  |  |  | 17,350 |  |  | 18,893 |  |  |  |  | 18,893 |
Licensing agreements and other(c) |  | 461 |  |  |  |  | 461 |  |  | 670 |  |  |  |  | 670 |
|  | 17,811 |  |  |  |  | 17,811 |  |  | 19,563 |  |  |  |  | 19,563 |
Identifiable intangible assets(d) |  | $ | 122,660 |  |  | $ | (71,337) |  |  | $ | 51,324 |  |  | $ | 122,961 |  |  | $ | (67,549) |  |  | $ | 55,411 |
(a)The changes in the gross carrying amounts primarily reflect the transfer of $600 million and $590 million from IPR&D to developed technology rights for Padcev and talazoparib (Talzenna), respectively, as well as the impact of foreign exchange. (b)The decrease in the gross carrying amount reflects an impairment of $260 million (see Note 4). (c)The decrease in the gross carrying amount reflects an impairment of $210 million (see Note 4). (d)The decrease is primarily due to amortization expense of $3.6 billion. B. Goodwill As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the first quarter of 2025 (see Note 13A), our goodwill was reallocated among impacted reporting units. We completed the re-allocation during the first quarter of 2025 and concluded that none of our goodwill was impaired. All goodwill continues to be assigned within the Biopharma reportable segment.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration